A new study has found that a single intravenous infusion of ketamine can provide rapid relief from severe depression symptoms and suicidal thoughts within hours of treatment, according to researchers.

The findings focus on patients with treatment-resistant depression who have not responded to traditional antidepressant medications. Ketamine, originally developed as an anesthetic, has emerged as a controversial but potentially breakthrough treatment for severe mental health conditions.

Researchers reported that the drug's effects were observed within hours rather than the weeks typically required for conventional antidepressants to take effect. This rapid onset could be particularly significant for patients experiencing acute suicidal ideation who need immediate intervention.

The study adds to growing evidence supporting ketamine's use in psychiatry, though the drug remains controversial due to its potential for abuse and side effects. The treatment requires medical supervision and is typically administered in clinical settings.

Ketamine works differently from traditional antidepressants by targeting the brain's NMDA receptors rather than serotonin pathways. This mechanism may explain its ability to provide faster relief for patients who have exhausted other treatment options.

The research represents a significant development in treating severe depression, particularly for cases where immediate intervention is critical and standard treatments have proven ineffective.